Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling
pathways, provides novel opportunities for cancer-drug discovery. As a key regulator of …

To date, there are no effective targeted pan-KRAS therapies. In-depth characterization of BI-3406
activity and identification of MEK inhibitors as effective combination partners provide …

The triple-angiokinase inhibitor nintedanib is an orally available, potent, and selective inhibitor
of tumor angiogenesis by blocking the tyrosine kinase activities of vascular endothelial …

10.7554/eLife.26980.001 Recent genome analyses have identified recurrent mutations in
the cohesin complex in a wide range of human cancers. Here we demonstrate that the most …

10.7554/eLife.43333.001 Targeted cancer therapy is based on exploiting selective dependencies
of tumor cells. By leveraging recent functional screening data of cancer cell lines we …

Oncogenic alterations in human epidermal growth factor receptor 2 (HER2) occur in
approximately 2% of patients with non-small cell lung cancer and predominantly affect the tyrosine …

Efforts to improve the anti-tumor response to KRAS G12C targeted therapy have benefited
from leveraging combination approaches. Here, we compare the anti-tumor response induced …

The cohesin subunit STAG2 has emerged as a recurrently inactivated tumor suppressor in
human cancers. Using candidate approaches, recent studies have revealed a synthetic lethal …

Loss of WRN, a DNA repair helicase, was identified as a strong vulnerability of microsatellite
instable (MSI) cancers, making WRN a promising drug target. We show that ATP binding …

• The recent accelerated approval of the KRASG12C mutantselective inhibitor Sotorasib (AMG
510) for the treatment of 2nd line KRASG12C mutation-positive NSCLC patients marks …